Ligand Presents Encouraging Results From Type 2 Diabetes Trial Testing Experimental Therapy
News, Type 2 Diabetes News
Ligand Pharmaceuticals Inc. recently presented encouraging results from a study to evaluate LGD-6972, a novel glucagon receptor antagonist, as a treatment for type 2 diabetes mellitus at the 75th Scientific Sessions of the American Diabetes Association in ... Read more